Business
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook
Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Tegoprubart continues to be used as key component of immunosuppression regimen in xenotransplants, including three transplants of a genetically modified p
About this update from Eledon Pharmaceuticals, Inc.
[{"type":"image","alt":"Eledon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Eledon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fe3DFQlar3TdaQ4TB5I5xg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a724d231d4a058286f024bf497bd49c9","width":300,"height":76}},"lazy":false},{"type":"text","content":"Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development","length":174,"tagName":"p"},{"type":"text","content":"Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study","length":170,"tagName":"p"},{"type":"text","content":"Tegoprubart continues to be used as key component of immunosuppression regimen in xenotransplants, including three transplants of a genetically modified pig kidney into a human at Massachusetts General Hospital","length":210,"tagName":"p"},{"type":"text","content":"Completed $57.5 million financing, with funds expected to support operations into 2Q 2027","length":89,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced a summary of 2025 accomplishments and provided guidance for anticipated upcoming 2026 business milestones.","length":227,"tagName":"p"},{"type":"text","content":"“2025 was a significant year for Eledon as we achieved multiple key milestones across our tegoprubart clinical programs in kidney allotransplantation, islet transplantation and xenotransplantation. We were particularly encouraged by results from our Phase 2 BESTOW trial, presented at ASN Kidney Week in November, which further validated the favorable safety and tolerability profile of tegoprubart, reducing the metabolic, neurologic and cardiovascular toxicities commonly associated with tacrolimus,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “We look forward to engaging with regulatory authorities, including the FDA, as we advance tegoprubar...